Steroids have been used for the treatment of Guillain-Barré Syndrome (GBS) since the 1950s, while their clinical efficacy remains poorly defined. Most randomized controlled trials after the 1970s yielded no clues for significant differences between steroid therapy and symptomatic supportive therapy, while after adjusting the factors that affected the biases, the reanalysis of the two trials with the largest number of samples among them showed that intravenous methylprednisolone was superior to symptomatic supportive therapy, or its combination with intravenous immunoglobulin exhibited superior effects. To date, there is still no strong evidence proving or denying the efficacy of high-dose methylprednisolone, and further studies are still merited for issues regarding steroids for GBS.
展开▼
